Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Locus Biosciences
Locus Biosciences is a precision medicine company revolutionizing the treatment of bacterial infections and addressing unmet medical needs in immunology, oncology, and CNS disorders through…
Locus Biosciences
Locus Biosciences is a precision medicine company revolutionizing the treatment of bacterial infections and addressing unmet medical needs in immunology, oncology, and CNS disorders through…
TL;DR
Stage: Clinical-stage
Lead asset: LBP-EC01 (E. coli)
Platform: CRISPR-Cas3–enhanced bacteriophage therapeutics (crPhage™) with AI/robotics-driven discovery
Founded: 2015
Recent financing: $35M financing announced May 18, 2022
Company Overview
Problem Domain
Bacterial infections and related unmet needs across infectious disease, immunology, oncology, and CNS disorders.
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
19,000,000
Series A closed Nov 14, 2017; additional investors included Tencent Holdings, Abstract Ventures and others.
35,000,000
Completed $35M financing which included Series B equity and conversion of an earlier convertible note.
25,000,000
Secured a credit facility of up to $25M for milestone-based drawdowns.
20,000,000
Exclusive collaboration with upfront payment and potential milestone payments reported under the deal.
Investor Signal
“Artis Ventures, Tencent Holdings, Abstract Ventures, Viking Global Investors, Johnson & Johnson Innovation, Hercules Capital, CARB-X, BARDA, Discovery Innovations”